QuidelOrtho Corp - רווח נקי למניה בארבעת הרבעונים האחרונים QDEL

Risks of declining demand for COVID tests have been mitigated, yet equipment integration and regulatory pressure on margins remain relevant. Process optimization is based on the outsourcing of logistics and component manufacturing. Annual EPS growth according to financial statements (TTM) demonstrates profit dynamics, where the current level is around 68.50. QuidelOrtho (QDEL) leads in rapid diagnostics, supplying cardiac marker and influenza tests to clinics and pharmacies.

Year-over-year EPS growth (TTM) measures the percentage change in net income per share over a rolling twelve-month period, reflecting the actual efficiency of capital generation. By analyzing annual EPS growth based on financial statements (TTM), an investor separates the systemic resilience of QuidelOrtho (QDEL) from market noise, assessing how costs for the environmental modernization of packaging and equipment impact the business's bottom-line profitability.